COPD急性加重后呼吸支持质量监测研究:比较医院与家庭无创通气
Rescue2-monitor是一项开放标签、前瞻性随机对照优效性临床试验,纳入急性高碳酸血症呼吸衰竭后的高碳酸血症COPD患者,比较三种家庭无创通气策略与无家庭无创通气对无再入院生存的影响,主要目标是证明任一家庭策略均优于无家庭策略。
要点
- 研究比较家庭无创通气三种策略与无家庭通气对无再入院生存的影响
- 靶向组接受个体化通气设置与广泛监测
- 考虑心功能不全、OSA等合并症对通气结局的影响
核心结论
- 研究旨在证明三种家庭无创通气策略(救援、非靶向、靶向)中任一策略较无家庭无创通气均可改善无再入院生存。
- 个体化适配患者表型的长期无创通气可能改善预后、减少再入院并预防死亡。
研究设计与样本
- 开放标签、前瞻性随机对照优效性临床试验(Rescue2-monitor,NCT03890224,2019年3月26日注册)。
- 研究对象为急性高碳酸血症呼吸衰竭后的高碳酸血症COPD患者。
关键数值与推荐
- 主要目标为证明3种家庭无创通气策略(救援、非靶向、靶向)任一较无家庭无创通气改善无再入院生存。
- 靶向组接受个体化(靶向)通气设置与广泛监测。
临床怎么用
- 对急性高碳酸血症呼吸衰竭后的高碳酸血症COPD患者,可考虑家庭无创通气并监测夜间通气质量。
- 根据患者表型个体化调整通气设置可能有助于改善预后。
局限性
- 研究为开放标签设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic obstructive pulmonary disease (COPD) is expected to be the 3rd leading cause of death worldwide by 2020. Despite improvements in survival by using acute non-invasive ventilation (NIV) to treat patients with exacerbations of COPD complicated by acute hypercapnic respiratory failure (AHRF), these patients are at high risk of readmission and further life-threatening events, including death. Recent studies suggested that NIV at home can reduce readmissions, but in a small proportion of patients, and with a high level of expertise. Other studies, however, do not show any benefit of home NIV. This could be related to the fact that respiratory failure in patients with stable COPD and their response to mechanical ventilation are influenced by several pathophysiological factors which frequently coexist in the same patient to varying degrees. These pathophysiological factors might influence the success of home NIV in stable COPD, thus long-term NIV specifically adapted to a patient's "phenotype" is likely to improve prognosis, reduce readmission to hospital, and prevent death. In view of this conundrum, Rescue2-monitor (R2M), an open-label, prospective randomized, controlled study performed in patients with hypercapnic COPD post-AHRF, will investigate the impact of the quality of nocturnal NIV on the readmission-free survival. The primary objective is to show that any of 3 home NIV strategies ("rescue," "non-targeted," and "targeted") will improve readmission-free survival in comparison to no-home NIV. The "targeted" group of patients will receive a treatment with personalized (targeted) ventilation settings and extensive monitoring. Furthermore, the influence of comorbidities typical for COPD patients, such as cardiac insufficiency, OSA, or associated asthma, on ventilation outcomes will be taken into consideration and reasons for non-inclusion of patients will be recorded in order to evaluate the percentage of ventilated COPD patients that are screening failures. ClinicalTrials.gov NCT03890224 . Registered on March 26, 2019.
引用
- Respiratory support in COPD patients after acute exacerbation with monitoring the quality of support (Rescue2-monitor): an open-label, prospective randomized, controlled, superiority clinical trial comparing hospital- versus home-based acute non-invasive ventilation for patients with hypercapnic chronic obstructive pulmonary disease. Trials. 2020. PMID: 33092618. doi:10.1186/s13063-020-04672-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。